Recruiting
Phase 2

Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

Sponsor:

Verona Pharma plc

Code:

NCT05270525

Conditions

COPD

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

Ensifentrine

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information